Form 8-K - Current report:
SEC Accession No. 0001493152-24-008601
Filing Date
2024-03-01
Accepted
2024-03-01 17:24:28
Documents
16
Period of Report
2024-02-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48991
2 ex3-1.htm EX-3.1 4876
  Complete submission text file 0001493152-24-008601.txt   282734

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20240228.xsd EX-101.SCH 3893
4 XBRL DEFINITION FILE cldi-20240228_def.xml EX-101.DEF 27245
5 XBRL LABEL FILE cldi-20240228_lab.xml EX-101.LAB 37745
6 XBRL PRESENTATION FILE cldi-20240228_pre.xml EX-101.PRE 25866
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6445
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24711706
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)